154 related articles for article (PubMed ID: 27762892)
1. Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View.
Ronfard V; Vertès AA; May MH; Dupraz A; van Dyke ME; Bayon Y
Tissue Eng Part B Rev; 2017 Apr; 23(2):199-210. PubMed ID: 27762892
[TBL] [Abstract][Full Text] [Related]
2. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
[TBL] [Abstract][Full Text] [Related]
3. How Regenerative Medicine Stakeholders Adapt to Ever-Changing Technology and Regulatory Challenges? Snapshots from the World TERMIS Industry Symposium (September 10, 2015, Boston).
Bayon Y; Van Dyke M; Buelher R; Tubo R; Bertram T; Malfroy-Camine B; Rathman M; Ronfard V
Tissue Eng Part B Rev; 2017 Apr; 23(2):159-162. PubMed ID: 27771996
[TBL] [Abstract][Full Text] [Related]
4. Enhancing Tissue Engineering and Regenerative Medicine Product Commercialization: The Role of Science in Regulatory Decision-Making for the TE/RM Product Development.
Bertram TA; Johnson PC; Tawil BJ; Van Dyke M; Hellman KB
Tissue Eng Part A; 2015 Oct; 21(19-20):2476-9. PubMed ID: 26222734
[TBL] [Abstract][Full Text] [Related]
5. Translating cell-based regenerative medicines from research to successful products: challenges and solutions.
Bayon Y; Vertès AA; Ronfard V; Egloff M; Snykers S; Salinas GF; Thomas R; Girling A; Lilford R; Clermont G; Kemp P
Tissue Eng Part B Rev; 2014 Aug; 20(4):246-56. PubMed ID: 24754565
[TBL] [Abstract][Full Text] [Related]
6. Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.
Bayon Y; Vertès AA; Ronfard V; Culme-Seymour E; Mason C; Stroemer P; Najimi M; Sokal E; Wilson C; Barone J; Aras R; Chiesi A
Tissue Eng Part B Rev; 2015 Dec; 21(6):560-71. PubMed ID: 26179129
[TBL] [Abstract][Full Text] [Related]
7. Promissory identities: Sociotechnical representations & innovation in regenerative medicine.
Gardner J; Higham R; Faulkner A; Webster A
Soc Sci Med; 2017 Feb; 174():70-78. PubMed ID: 28012432
[TBL] [Abstract][Full Text] [Related]
8. Are there specific translational challenges in regenerative medicine? Lessons from other fields.
Gardner J; Faulkner A; Mahalatchimy A; Webster A
Regen Med; 2015; 10(7):885-95. PubMed ID: 26541074
[TBL] [Abstract][Full Text] [Related]
9. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
10. Regenerative medicine in Brazil: small but innovative.
McMahon DS; Singer PA; Daar AS; Thorsteinsdóttir H
Regen Med; 2010 Nov; 5(6):863-76. PubMed ID: 21082887
[TBL] [Abstract][Full Text] [Related]
11. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.
Mahalatchimy A; Faulkner A
Regen Med; 2017 Sep; 12(6):611-622. PubMed ID: 28972450
[TBL] [Abstract][Full Text] [Related]
12. Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem.
Banda G; Tait J; Mittra J
Clin Ther; 2018 Jul; 40(7):1084-1094. PubMed ID: 30017170
[TBL] [Abstract][Full Text] [Related]
13. Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine.
Grigorian-Shamagian L; Sanz-Ruiz R; Climent A; Badimon L; Barile L; Bolli R; Chamuleau S; Grobbee DE; Janssens S; Kastrup J; Kragten-Tabatabaie L; Madonna R; Mathur A; Menasché P; Pompilio G; Prosper F; Sena E; Smart N; Zimmermann WH; Fernández-Avilés F
Cardiovasc Res; 2021 May; 117(6):1428-1433. PubMed ID: 33258961
[TBL] [Abstract][Full Text] [Related]
14. Global strategic partnerships in regenerative medicine.
French A; Suh JY; Suh CY; Rubin L; Barker R; Bure K; Reeve B; Brindley DA
Trends Biotechnol; 2014 Sep; 32(9):436-40. PubMed ID: 25150363
[TBL] [Abstract][Full Text] [Related]
15. Can Regenerative Medicine Help Close the Gap Between the Medicine Pipeline and Public Health Burden of Cardiovascular and Musculoskeletal Diseases?
Hossain I; Milne C
Clin Ther; 2018 Jul; 40(7):1066-1075. PubMed ID: 30029792
[TBL] [Abstract][Full Text] [Related]
16. Ethical implications of regenerative medicine in orthopedics: an empirical study with surgeons and scientists in the field.
Niemansburg SL; van Delden JJ; Oner FC; Dhert WJ; Bredenoord AL
Spine J; 2014 Jun; 14(6):1029-35. PubMed ID: 24184644
[TBL] [Abstract][Full Text] [Related]
17. Critical issues for effective collaboration between academia and industry in the field of regenerative medicine in Japan.
Tsubouchi M; Morishita R; Tabata Y; Matsui S; Kawakami K
Regen Med; 2008 Jul; 3(4):497-504. PubMed ID: 18588472
[TBL] [Abstract][Full Text] [Related]
18. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
Ginty PJ; Rayment EA; Hourd P; Williams DJ
Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
[TBL] [Abstract][Full Text] [Related]
19. Regenerative medicine: challenges and perspectives for successful therapies.
Viswanathan S; Joshi C
Curr Top Microbiol Immunol; 2013; 367():101-12. PubMed ID: 23208552
[TBL] [Abstract][Full Text] [Related]
20. Recent Progress in European Advanced Therapy Medicinal Products and Beyond.
Yu TTL; Gupta P; Ronfard V; Vertès AA; Bayon Y
Front Bioeng Biotechnol; 2018; 6():130. PubMed ID: 30298129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
